Cargando…
A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
The healthy immune system eliminates pathogens and maintains tissue homeostasis through extraordinarily complex networks with feedback systems while avoiding potentially massive tissue destruction. Many parameters influence humoral and cellular vaccine responses, including intrinsic and extrinsic, e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343749/ https://www.ncbi.nlm.nih.gov/pubmed/36076589 http://dx.doi.org/10.1016/j.biopha.2022.113499 |
_version_ | 1784761058698723328 |
---|---|
author | Mohamed, Yasser El-Maradny, Yousra A. Saleh, Ahmed K. Nayl, AbdElAziz A. El-Gendi, Hamada El-Fakharany, Esmail M. |
author_facet | Mohamed, Yasser El-Maradny, Yousra A. Saleh, Ahmed K. Nayl, AbdElAziz A. El-Gendi, Hamada El-Fakharany, Esmail M. |
author_sort | Mohamed, Yasser |
collection | PubMed |
description | The healthy immune system eliminates pathogens and maintains tissue homeostasis through extraordinarily complex networks with feedback systems while avoiding potentially massive tissue destruction. Many parameters influence humoral and cellular vaccine responses, including intrinsic and extrinsic, environmental, and behavioral, nutritional, perinatal and administrative parameters. The relative contributions of persisting antibodies and immune memory as well as the determinants of immune memory induction, to protect against specific diseases are the main parameters of long-term vaccine efficacy. Natural and vaccine-induced immunity and monoclonal antibody immunotherapeutic, may be evaded by SARS-CoV-2 variants. Besides the complications of the production of COVID-19 vaccinations, there is no effective single treatment against COVID-19. However, administration of a combined treatment at different stages of COVID-19 infection may offer some cure assistance. Combination treatment of antiviral drugs and immunomodulatory drugs may reduce inflammation in critical COVID-19 patients with cytokine release syndrome. Molnupiravir, remdesivir and paxlovid are the approved antiviral agents that may reduce the recovery time. In addition, immunomodulatory drugs such as lactoferrin and monoclonal antibodies are used to control inflammatory responses in their respective auto-immune conditions. Therefore, the widespread occurrence of highly transmissible variants like Delta and Omicron indicates that there is still a lot of work to be done in designing efficient vaccines and medicines for COVID-19. In this review, we briefly discussed the immunological response against SARS-CoV-2 and the vaccines approved by the World Health Organization (WHO) for COVID-19, their mechanisms, and side effects. Moreover, we mentioned various treatment trials and strategies for COVID-19. |
format | Online Article Text |
id | pubmed-9343749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93437492022-08-02 A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Mohamed, Yasser El-Maradny, Yousra A. Saleh, Ahmed K. Nayl, AbdElAziz A. El-Gendi, Hamada El-Fakharany, Esmail M. Biomed Pharmacother Review The healthy immune system eliminates pathogens and maintains tissue homeostasis through extraordinarily complex networks with feedback systems while avoiding potentially massive tissue destruction. Many parameters influence humoral and cellular vaccine responses, including intrinsic and extrinsic, environmental, and behavioral, nutritional, perinatal and administrative parameters. The relative contributions of persisting antibodies and immune memory as well as the determinants of immune memory induction, to protect against specific diseases are the main parameters of long-term vaccine efficacy. Natural and vaccine-induced immunity and monoclonal antibody immunotherapeutic, may be evaded by SARS-CoV-2 variants. Besides the complications of the production of COVID-19 vaccinations, there is no effective single treatment against COVID-19. However, administration of a combined treatment at different stages of COVID-19 infection may offer some cure assistance. Combination treatment of antiviral drugs and immunomodulatory drugs may reduce inflammation in critical COVID-19 patients with cytokine release syndrome. Molnupiravir, remdesivir and paxlovid are the approved antiviral agents that may reduce the recovery time. In addition, immunomodulatory drugs such as lactoferrin and monoclonal antibodies are used to control inflammatory responses in their respective auto-immune conditions. Therefore, the widespread occurrence of highly transmissible variants like Delta and Omicron indicates that there is still a lot of work to be done in designing efficient vaccines and medicines for COVID-19. In this review, we briefly discussed the immunological response against SARS-CoV-2 and the vaccines approved by the World Health Organization (WHO) for COVID-19, their mechanisms, and side effects. Moreover, we mentioned various treatment trials and strategies for COVID-19. The Author(s). Published by Elsevier Masson SAS. 2022-09 2022-08-02 /pmc/articles/PMC9343749/ /pubmed/36076589 http://dx.doi.org/10.1016/j.biopha.2022.113499 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Mohamed, Yasser El-Maradny, Yousra A. Saleh, Ahmed K. Nayl, AbdElAziz A. El-Gendi, Hamada El-Fakharany, Esmail M. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title_full | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title_fullStr | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title_full_unstemmed | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title_short | A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. |
title_sort | comprehensive insight into current control of covid-19: immunogenicity, vaccination, and treatment. |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343749/ https://www.ncbi.nlm.nih.gov/pubmed/36076589 http://dx.doi.org/10.1016/j.biopha.2022.113499 |
work_keys_str_mv | AT mohamedyasser acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elmaradnyyousraa acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT salehahmedk acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT naylabdelaziza acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elgendihamada acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elfakharanyesmailm acomprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT mohamedyasser comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elmaradnyyousraa comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT salehahmedk comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT naylabdelaziza comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elgendihamada comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment AT elfakharanyesmailm comprehensiveinsightintocurrentcontrolofcovid19immunogenicityvaccinationandtreatment |